# A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis

> **NCT01177800** · PHASE3 · COMPLETED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 129 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT01177800
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-02
- **Final completion:** 2010-09
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2014-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01177800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01177800, "A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01177800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*